Introduction {#Sec1}
============

Breast cancer is the most commonly diagnosed cancer, and the leading cause of cancer-related deaths, in women worldwide \[[@CR1]\]. Cases are usually classified by their expression of estrogen receptors (ER) progesterone receptors (PR), and human epidermal growth factor-2 receptors (HER2), which together predict treatment response and prognosis \[[@CR2]\]. Although hormone receptor (HR)^+^ breast cancers have many effective treatment options, fewer targeted therapies are available for triple receptor-negative breast cancers (TNBCs). Currently, some progress has been made in classifying TNBCs into several distinct subtypes using gene expression profiling analyses, and some kinases and agents were identified as potential druggable targets \[[@CR3], [@CR4]\], but the therapeutic implications are yet to be elucidated \[[@CR5]\]. Thus, characterization of novel molecular biomarkers is critically required for the treatment of TNBCs.

Lysophosphatidic acid (LPA) receptors are specific G protein-coupled receptors binding with LPA, which mediates a variety of biological processes, such as cell proliferation, migration, invasion and differentiation \[[@CR6]\]. At least six LPA receptors (LPA~1--6~) are currently identified, and their emerging roles in tumorigenesis have been demonstrated both in vitro and in vivo \[[@CR7]\]. In breast tissue, LPA~1~ and LPA~2~ are broadly expressed in either normal or abnormal mammary epithelial cells, whereas expression levels of LPA~3--6~ are more restricted or undetectable, which may account for the various biological effects of LPA \[[@CR8]--[@CR10]\]. Overexpression of LPA~1~ and LPA~2~ was readily observed in breast cancers with redundant mediation functions in multiple endogenous LPA responses, including cancer cell growth, metastasis, angiogenesis, and chemoresistance \[[@CR8], [@CR11]--[@CR13]\]. In contrast, less is known about the role of LPA~3~ in breast cancer initiation and progression. Previous published data showed that LPA~3~ was higher expression in poorly differentiated breast cancers than well-differentiated tumors \[[@CR14], [@CR15]\], which suggests that LPA~3~ contributes to breast cancer progression.

Although the LPA receptors have been shown to affect breast cancer initiation and progression, the exact expression patterns and functions in TNBCs have not been fully examined. In the present study, we characterized the expression of LPA~1--3~ in human normal, benign, and malignant breast tissues and cell lines, and analyzed correlations with clinical and pathological findings to highlight the possible roles of LPA receptors in the development and treatment of TNBCs.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Specimens of normal breast (*n* = 37), mammaries with benign disease (*n* = 55), and breast cancer (*n* = 82) were collected from the First Affiliated Hospital of Xi'an Jiaotong University. This study was approved by the IRB of Xi'an Jiaotong University School of Medicine. All tissues were pathologically examined. Written informed consent forms were obtained from all subjects, and all clinical investigation had been conducted according to the principles expressed in the Declaration of Helsinki.

RNA isolation and quantitative real-time PCR {#Sec4}
--------------------------------------------

Tissues or cells were lysed in the Qiagen RLT lysis buffer (Qiagen, USA). RNA was extracted with an RNeasy mini kit (Qiagen, USA) and reverse transcribed by M-MLV reverse transcriptase (Invitrogen, USA). Quantitative real-time PCR was performed on a Bio-Rad iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories, USA) with a SYBR Green I Master Mix (TAKARA, Japan). PCRs were performed in triplicate, and the relative gene expression was calculated against GAPDH. Primer pairs used in this study were as follows: GAPDH: F, 5′-GAAGGTGAAGGTCGGAGT-3′/R, 5′-GAAGATGGTGATGGGATTTC-3′; LPA~1~: F, 5′-AATCGAGAGGCACATTACGG-3′/R, 5′-GTTGAAAATGGCCCAGAAGA-3′; LPA~2~: F, 5′-TTGTCTTCCTGCTCATGGTG-3′/R, 5′-TCAGCATCTCGGCAAGAGTA-3′; LPA~3~: F, 5′-TGCTCATTTTGCTTGTCTGG-3′/R, 5′-GCCATACATGTCCTCGTCCT-3′.

Immunohistochemistry (IHC) analysis {#Sec5}
-----------------------------------

Formalin-fixed paraffin-embedded sections (5 µm thick) of the normal breast, breast with benign diseases, and breast cancers were analyzed by IHC with the primary LPA~1--3~ antibody (1:100) and a biotin-conjugated secondary antibody. For IHC quantification, the sections were analyzed using Nikon TE2000-s microscope (Melville, USA). Four randomly selected areas were photographed at 40× magnification using a QimageRetiga 2000R camera (Surrey, Canada). The integral optical density (IOD) of immunoreactivity was calculated using the Image-Pro Plus image analysis software (Media Cybernetics, USA).

Cell lines and culture {#Sec6}
----------------------

The MCF-10A and MCF-7 cells were obtained from Sagene Inc., (Guangzhou, China), and the MCF-12A, T47D, MDA-MB-231, and MDA-MB-157 cells were obtained from ATCC (Manassas, USA). All cell lines were maintained in a humidified atmosphere at 37 °C with 5 % CO~2~. MCF-10A, MCF-12A, and MCF-7 cells were cultured in DMEM with glutamine, 10 % FBS (Gibco, USA), and 100 μg/mL penicillin/streptomycin (P/S). T47D were cultured in RPMI1640 with glutamine, 10 % FBS (Gibco), and 100 μg/mL P/S. MDA-MB-231 and MDA-MB-157 cultured in Leibovitz's L-15 Medium (ATCC, USA) with 10 % FBS (Gibco) and 100 μg/mL P/S.

Western blot analyses {#Sec7}
---------------------

Western blot analyses were conducted using standard procedures, and proteins were detected using primary antibodies and fluorescent secondary antibodies (IRDye800CW-conjugated or IRDye680-conjugated anti-species IgG, Li-Cor Biosciences, Lincoln, NE, USA). The fluorescent signals were captured on an Odyssey Infrared Imaging System (Li-Cor Biosciences) with both 700- and 800-nm channels. Boxes were manually placed around each band of interest, and the software returned near-infrared fluorescent values of raw intensity with background subtraction (Odyssey 3.0 analytical software, Li-Cor Biosciences).

shRNA transfection {#Sec8}
------------------

Six-well plates were seeded with 5 × 10^4^ cells/well in 2 mL media 24 h before transfection; cells were 80--90 % confluent at transfection. Cells were transfected with LPA~3~ shRNA (100 pmol/well, Santa Cruz Biotechnology, USA) using Lipofectamine 2000 Reagent (Life Technologies, USA) according to the manufacturer's instruction. After 48 h of transfection, cells were selected using puromycin for 2 weeks. Stable transductants were pooled.

MTT assays {#Sec9}
----------

Cells were seeded at a density of 5 × 10^3^ cells/well in 96-well plates at a final volume of 180 µL in incubation, at 37 °C, with 5 % CO~2~. After different time incubation, 20 µL of 5 mg/mL solution of MTT (Sigma, MO, USA) in PBS was added to each well, and plates were then incubated for 4 h at 37 °C. Reaction crystals were then solubilized in 100 % dimethylsulfoxide (Sigma) 20 µL/well and shaken for 15 min. Absorbance of each well was measured on a multidetection microplate reader (BMG LABTECH, USA) at a wavelength of 570 nm.

Cell migration and invasion Assays {#Sec10}
----------------------------------

Migration and invasion assays were conducted using transwell plates with 8-μm pore size membranes (Corning Inc., USA) as described previously \[[@CR16]\]. After incubation for 4 h (for migration assays) or 24 h (for invasion assays), cells remaining in the upper side of the filter were removed with cotton swabs. The cells attached on the lower surface were fixed and stained using crystal violet and washed with water. Cells were counted with five high power fields per membrane, and results were presented as the mean number of cells migrated per field per membrane. All experiments were conducted in triplicate.

Statistical analyses {#Sec11}
--------------------

Continuous variables were summarized as means with standard deviations (SD) across the healthy control, benign disease, and cancer groups. One-way ANOVA was used to test the overall difference, and Student's *t* test was used to test the pairwise difference across disease statuses. Correlation between two different groups was tested by Pearson's correlation coefficient. *P* \< 0.05 was considered significant. All analyses were performed using SPSS software version 19.0 (IBM, USA).

Results {#Sec12}
=======

Expression patterns of LPA~1--3~ in breast tissues {#Sec13}
--------------------------------------------------

We evaluated mRNA expression of LPA~1--3~ in normal, benign, and malignant breast epithelium; mRNA levels were quantified against *GAPDH*. As shown in Fig. [1](#Fig1){ref-type="fig"}a, breast tissues predominantly expressed LPA~1~ and LPA~2~, whereas LPA~3~ expression was weakly but detectable in all specimens. Similar levels of LPA~1~ mRNA were detected in normal, benign, and carcinoma tissues (0.11 ± 0.058 vs. 0.13 ± 0.044 vs. 0.13 ± 0.034, *P* = 0.789; Fig. [1](#Fig1){ref-type="fig"}b). However, LPA~2~ mRNA levels in breast cancers were significantly higher than that in normal tissue (0.17 ± 0.070 vs. 0.13 ± 0.072, *P* = 0.0002; Fig. [1](#Fig1){ref-type="fig"}c). Although low levels of LPA~3~ were observed in all breast tissues, the cancer tissues exhibited a greater expression of LPA~3~ than did normal (0.05 ± 0.023 vs. 0.02 ± 0.002, *P* \< 0.001) or benign-disease tissues (0.05 ± 0.023 vs. 0.03 ± 0.002, *P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}d). Notably, LPA~3~ expression was also greater in benign-disease tissue than in normal tissue (0.03 ± 0.002 vs. 0.02 ± 0.002, *P* = 0.009; Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1mRNA expression of LPA receptor 1-3 in breast tissues. **a** To determine whether the samples expressed LPA receptors, quantitative real-time PCR was performed by LPA~1~, LPA~2~, and LPA~3~ primers. The relative gene expression was calculated against GAPDH. **b** The relative LPA~1~ mRNA expression in normal breast epithelium, mammary with benign disease, and malignant tissues. **c** The relative LPA~2~ mRNA expression in normal breast epithelium, mammary with benign disease, and malignant tissues. **d** The relative LPA~3~ mRNA expression in normal breast epithelium, mammary with benign disease, and malignant tissues. \*\*\**P* \< 0.001

We also immunohistochemically evaluated expression of LPA receptor proteins in the same specimens (Fig. [2](#Fig2){ref-type="fig"}a). LPA~1--3~ was detectable in the cell membrane and cytoplasm in most specimens (113/119 of LPA~1~, 116/119 of LPA~2~, and 110/119 of LPA~3~). As with the mRNA expression, enhanced staining for LPA~2~ and LPA~3~ protein was clearly detected in carcinomas in comparison with normal epithelium or benign-disease tissues (Fig. [2](#Fig2){ref-type="fig"}c, d), whereas LPA~1~ expression did not differ significantly between different groups (Fig. [2](#Fig2){ref-type="fig"}b). Protein immunoreactivity significant correlated with relative mRNA expression (*r* = 0.592, *P* \< 0.001).Fig. 2Protein levels of LPA receptor 1-3 in different breast tissues. **a** Immunostains for LPA receptor 1-3 in normal, benign disease and malignant breast tissue. **b**--**d** Quantification of immunostains for LPA receptor 1-3 by IOD analysis. \**P* \< 0.05; \*\*\**P* \< 0.001

Relationship between LPA~1--3~ mRNA expression and clinical parameters in breast cancer patients {#Sec14}
------------------------------------------------------------------------------------------------

Relationships between LPA~1--3~ mRNA expression and clinical or pathological findings in 82 cases are presented in Table [1](#Tab1){ref-type="table"}. LPA~1~ expression did not correlate with any clinical parameters. Higher expression of LPA~2~ was seen in postmenopausal patients (*P* \< 0.05). The higher-stage tumors tended to express less LPA~2~, but not significantly (*P* = 0.095). The expression of LPA~3~ was associated with hormonal receptor status and lymph node metastases. ER^−^, PR^−^, or Her2^−^ tumors were more likely to express excess LPA~3~ than positive ones. Moreover, patients with lymph node metastases presented with higher LPA~3~ expression than patients without metastases (*P* \< 0.05).Table 1Relationship between LPA receptors expression and clinical parameters of breast cancerClinical parameters*N* (%)LPA~1~LPA~2~LPA~3~Age (years) \<5041 (50.0)0.134 ± 0.0390.173 ± 0.0640.043 ± 0.020 ≥5041 (50.0)0.133 ± 0.0450.172 ± 0.0650.051 ± 0.022Stage I14 (17.0)0.134 ± 0.0470.184 ± 0.0590.047 ± 0.030 II13 (15.9)0.141 ± 0.0420.178 ± 0.0580.048 ± 0.014 III20 (24.4)0.127 ± 0.0280.173 ± 0.0690.041 ± 0.016 IV35 (42.7)0.134 ± 0.0470.167 ± 0.0660.050 ± 0.022Grade 129 (35.4)0.134 ± 0.0360.177 ± 0.0600.040 ± 0.016 237 (45.1)0.136 ± 0.0480.164 ± 0.0710.050 ± 0.026 316 (19.5)0.125 ± 0.0480.184 ± 0.0700.051 ± 0.017Tumor size ≤2.0 cm30 (36.6)0.124 ± 0.0360.173 ± 0.0630.049 ± 0.023 2.0--5.0 cm36 (43.9)0.143 ± 0.0460.177 ± 0.0680.049 ± 0.020 \>5.0 cm16 (19.5)0.130 ± 0.0390.163 ± 0.0580.037 ± 0.019Menopausal status Premenopausal32 (39.0)0.133 ± 0.0430.154 ± 0.046**\***0.043 ± 0.022 Postmenopausal50 (61.0)0.134 ± 0.0410.185 ± 0.0710.049 ± 0.021ER status Negative37 (45.1)0.133 ± 0.0450.169 ± 0.0600.057 ± 0.023\*\*\* Positive45 (54.9)0.134 ± 0.0390.176 ± 0.0670.038 ± 0.015PR status Negative43 (52.4)0.132 ± 0.0440.180 ± 0.0720.055 ± 0.023\*\*\* Positive39 (47.6)0.135 ± 0.0400.166 ± 0.0540.037 ± 0.014Her2 status Negative55 (67.1)0.135 ± 0.0430.164 ± 0.0550.051 ± 0.023\*\* Positive27 (32.9)0.131 ± 0.0410.191 ± 0.0770.038 ± 0.013Nodal metastasis Negative37 (45.1)0.132 ± 0.0420.177 ± 0.0640.034 ± 0.013\*\*\* Positive45 (54.9)0.135 ± 0.0420.170 ± 0.0640.057 ± 0.021\* *P* \< 0.05; \*\* *P* \< 0.01; \*\*\* *P* \< 0.001

Higher expression of LPA~3~ in TNBC tissues and cell lines {#Sec15}
----------------------------------------------------------

As LPA~3~ expression in carcinomas strongly correlated with HR status, we subsequently analyzed the distributions of LPA~3~ among different tumor immunophenotypes. Breast cancer patients were classified as luminal A, luminal B, and TNBC, based on their expression of ER, PR, Her2, and ki-67 \[[@CR17]\]. LPA~3~ expression differed significantly among tumors with different immunophenotypes (*P* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}a). The highest LPA~3~ protein level was demonstrated in the TNBCs whereas similar expressions were found between luminal A and luminal B carcinomas.Fig. 3High expression of LPA~3~ in TNBCs. **a** The relative LPA3 mRNA expression in breast cancer tissues from luminal A, luminal B and TNBC patients. **b** The relative LPA~3~ mRNA expression in six different breast cell lines was determined by quantitative real-time PCR. The results are presented as the mean ± SD against GAPDH obtained in three independent experiments. **c** Western blots were used to detect protein levels of LPA~3~ in six breast cell lines. Quantification of protein was presented as the mean ± SD of fluorescent values obtained in three independent experiments. ^†^Compared to normal mammary cells, *P* \< 0.05; ^‡^compared to normal mammary cells or non-TNBC cells, *P* \< 0.001

To confirm the expression profiles of LPA~3~ in TNBCs, we further detected the mRNA and protein levels of LPA~3~ in normal mammary epithelial cells and breast cancer cell lines with different molecular phenotypes. As expected, breast cancer cell lines (MCF-7, T47D, MDA-MB-231, and MDA-MB-157) expressed more LPA~3~ than normal immortal cells (MCF-10A and MCF-12A), and the highest expression of LPA~3~ was detected in the TNBC cells (MDA-MB-231 and MDA-MB-157) (Fig. [3](#Fig3){ref-type="fig"}b, c).

Inhibition of LPA~3~ by shRNA decreased migration and invasion of TNBC cells {#Sec16}
----------------------------------------------------------------------------

To further analyze the role of LPA~3~ in breast tumorigenesis, we conducted cell proliferation, migration, and invasion assays of LPA~3~- and control-shRNA-transfected breast epithelial cells, including normal immortal cells MCF-10A, luminal cells MCF-7, and TNBC cells MDA-MB-231. LPA~3~ was effectively down-regulated by shRNA in all three cell lines (Fig. [4](#Fig4){ref-type="fig"}a). Cell proliferation tested by MTT showed that suppression of LPA~3~ did not influence cell growth in all three cell lines (Fig. [4](#Fig4){ref-type="fig"}b). However, cells with LPA~3~-shRNA migrated significantly less than controls in MDA-MB-231 cells (Fig. [4](#Fig4){ref-type="fig"}c). Although LPA~3~-shRNA also reduced migration of MCF-7 cells, the inhibitory capacity was weaker than in MDA-MB-231 cells (Fig. [4](#Fig4){ref-type="fig"}c). We also assessed the effect of LPA~3~ knockdown on cellular invasion and revealed LPA~3~ loss significantly decreased invasion of MDA-MB-231 cells, but had less or no effect on MCF-10A and MCF-7 cells (Fig. [4](#Fig4){ref-type="fig"}d).Fig. 4Inhibition of LPA~3~ decreased migration and invasion of TNBC cells. **a** Expression of LPA~3~ was decreased by shRNA. MCF-10A, MCF-7, and MDA-MB-231 cells were transfected with control and LPA~3~ shRNA. Forty-eight hours later, cell lysates were analyzed by Western blots with anti-LPA~3~ antibody. **b** The effect of LPA~3~ on breast cancer cells growth, as measured using the MTT assay. The results are presented as the mean ± SD of fold increased to initiation obtained in 3 independent experiments. **c**, **d** Cell transwell assays were conducted to investigate the role of LPA~3~ on breast cancer cells migration (**c**) and invasion (**d**). The results are presented as the mean ± SD of cell number obtained in three independent experiments. \*\**P* \< 0.01; \*\*\**P* \< 0.001

Ki16425 dose-dependently suppressed migration and invasion of TNBC cells {#Sec17}
------------------------------------------------------------------------

We used Ki16425, an antagonist for LPA~1~ and LPA~3~, to confirm the critical roles of LPA~3~ in TNBC cells. We first showed that pre-treating MDA-MB-231 cells with Ki16425 did not influence cell viability (Fig. [5](#Fig5){ref-type="fig"}a). We then evaluated the effects of Ki16425 on migration and invasion of TNBC cells, using transwell assays. As shown in Fig. [5](#Fig5){ref-type="fig"}b, c, Ki16425 suppressed migration and invasion of MDA-MB-231 cells in a dose-dependent manner.Fig. 5Inactivated LPA~3~ by Ki16425 suppressed migration and invasion of TNBC cells. **a** MDA-MB-231 cells were treated with indicated concentrations of Ki16428 for 1 h, and then cell viability was measured using the MTT assay. The results are presented as the mean ± SD of fold increased to initiation obtained in 3 independent experiments. **b**, **c** Migration (**b**) and invasion (**c**) of MDA-MB-231 cells were inhibited by ki16425. MDA-MB-231 cells were pretreated with indicated concentrations of ki16425 for 1 h and then transferred to collagen- or matrigel-coated transwell chambers for migration and invasion experiments, respectively. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001

Discussion {#Sec18}
==========

LPA receptors are expressed by normal mammary epithelial cells, with aberrant expression occurring during breast cancer initiation and progression \[[@CR18]\]. In the present study, we found abnormal expression of LPA receptors in mammary carcinomas, and that LPA~2~ and LPA~3~ expression was enhanced in breast cancer compared with normal breast and benign-disease tissues, although the expression level of LPA~1~ was not significantly different between each subgroup. Particularly, we also showed significantly increased LPA~3~ expression in the TNBCs compared with other immunophenotype tumors. Subsequently, function analysis revealed that inhibition of LPA~3~ by shRNA or antagonist dramatically suppressed the migration and invasion ability of TNBC cells, but had no or less effect on normal or luminal-type cancer cells, which suggests a role for LPA~3~ in the pathophysiology of TNBCs.

Expression and function of LPA~1~ in the breast cancer have been studied extensively. Overexpression of LPA~1~ is readily observed in breast cancer cells \[[@CR19]\]. Manipulation of LPA~1~ level or function could alter the survival and metastatic ability of breast cancer cells both in vitro and in vivo \[[@CR11], [@CR12], [@CR14], [@CR20], [@CR21]\]. However, in our present research, LPA~1~ expression levels did not differ significantly between normal and malignant breast tissues. This inconsistency may result from tumor heterogeneity. In breast cancer, LPA~1~ is expressed in many cancer cell lines, but at various levels. It is most likely that LPA~1~ higher expressed in more aggressive cell lines, such as MDA-MB-231, and lower in less aggressive breast cancer cells, such as MCF-7 \[[@CR10], [@CR13], [@CR20], [@CR22], [@CR23]\]. In accord with cell lines, LPA~1~ mRNA was significantly more abundant in advanced stages of breast cancer compared with noninvasive stage breast tumors \[[@CR24]\]. Moreover, accumulating evidence indicates that the LPA~1~ contributes to the metastatic capability of breast cancers. Higher LPA~1~ expression is significantly related to positive node and bone metastases \[[@CR11], [@CR12]\], which implies that LPA~1~ affects breast cancer progression. However, some clinical studies found no major expression pattern for the LPA~1~ between breast cancer patients and normal controls \[[@CR8], [@CR25]\], which suggests that LPA~1~ has no role in breast cancer initiation.

From an evolutionary perspective, tumors can be as genetically and epigenetically heterogeneous cell populations, although most human tumors are monoclonal outgrowths descending from single progenitor cells \[[@CR26], [@CR27]\]. As tumor progression, genetic and epigenetic alterations occur in progeny cells. However, changes in LPA~1~ expression as they affect breast cancer initiation and progression are barely understood and require additional exploration.

Although the expression and functions of LPA~2~ have been the subject of fewer studies, increased LPA~2~ expression has been reported in invasive breast carcinoma \[[@CR8], [@CR14]\]. Transgenic mice that overexpress LPA~2~ showed higher incidence of mammary tumors with early onset than mice that overexpress LPA~1~, which implicates LPA~2~ in the initiation of breast cancer \[[@CR14]\]. In vitro studies, LPA~2~ has been verified to regulate LPA-induced breast cancer cells proliferation and migration through Erk or RhoA pathway \[[@CR23], [@CR28]\]. Recently, a literature also reported LPA~2~ involved in LPA-induced IL-6 and IL-8 expression, which promoted colony formation and cell survival of TNBCs \[[@CR29]\]. Together with our findings that LPA~2~ is more highly expressed in breast cancer patients, these combined data validate LPA~2~ as a potential therapeutic target for drug development and evaluation in breast cancer.

As with LPA~2~, little is known about the expression patterns of LPA~3~ in breast cancers. Until recently, Nikolay et al. indicated that LPA~3~ was higher expressed in human breast cancers, and most interesting LPA~3~ overexpression was associated with absence of ER and PR \[[@CR30]\], which suggests a function of LPA~3~ in HR^−^ carcinomas. Our studies confirmed that LPA~3~ was overexpression in ER^−^/PR^−^/Her2^−^ tumor cells and tissues when compared with normal breast epithelium and luminal-type cancers. Inhibition of LPA~3~ significantly decreased migration and invasion of TNBC cells but did not affect other immunotype breast cancers, reflecting on dominant metastatic roles of LPA~3~ in TNBCs.

Cancer metastasis is a complex biological event of multiple steps, one of which is epithelial to mesenchymal transition (EMT), a prelude to increased cellular motility and plasticity, which thereby enables cellular invasion \[[@CR31], [@CR32]\]. Initial evidence for a possible role of LPA and its receptors in EMT was derived from experiments in hepatocellular carcinoma and ovarian cancer by showing a proline-rich tyrosine kinase 2 (PYK2) or periostin (alias osteoblast-specific factor-2)-induced EMT, upon LPA treatment \[[@CR33], [@CR34]\]. In the breast cancer, Jahn et al. \[[@CR35]\] demonstrated that LPA~1~ is up-regulated in cells that underwent EMT and consequently led to an increased responsiveness to LPA after EMT. These results imply that the LPA receptors contribute to cell EMT. The roles of different LPA receptors in EMT clearly merit wider investigation.

As a receptor for LPA, LPA~3~ can promote cancer progression. However, the downstream pathways of LPA~3~ are rarely elucidated. Currently, evidences indicated that Yes-associated protein (YAP), a transcriptional factor of Hippo pathway, is a critical downstream mediatio of LPA~3~ in ovarian cancer \[[@CR36]\]. Thus, we invested the expression correlation between LPA~3~ and YAP protein and found that tumors with overexpression of LPA~3~ exhibited week YAP staining (data not shown). As YAP functions as a breast tumor suppressor \[[@CR37]\], LPA~3~-YAP pathway may involved in initiation and progression of breast cancers. Interesting, another study revealed that loss of YAP expression is associated with estrogen and PR negativity in breast carcinomas \[[@CR38]\]. Besides, in transgenic mice model, the ER, PR, and Her2 were significantly decreased in LPA~3~ overexpression mice when compared to wild-type mice \[[@CR14]\]. All together, LPA~3~, YAP, and hormonal receptors may interact in TNBC pathophysiology. However, the exact mechanism is unclear and requires further study.
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